ArticleExperimental and clinical psychopharmacology2026
The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.
Jermaine D Jones, Suky Martinez, Caroline Arout, Margaret Haney, Felipe Castillo, Jeanne Manubay, Freymon Perez, Rachel R Luba, Sandra D Comer
Abstract read
In one paragraphArticle in Experimental and clinical psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Jermaine D JonesDepartment of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center.ORCID 0000-0003-4476-2800 Suky MartinezDepartment of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine.
Caroline AroutDepartment of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center.
Margaret HaneyDepartment of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center.
Felipe CastilloDepartment of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center.
Jeanne ManubayDepartment of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center.
Freymon PerezDepartment of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center.
Rachel R LubaDepartment of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center.
Sandra D ComerDepartment of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center.
Funding
Translational Clinical Research Fellowship on Substance Use DisordersT32DA007294 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Frances Rudnick Levin, Diana M Martinez · 1993 to 2026
$9.3MNatural Language Processing Phenotyping of Spirituality and Resilience Among Individuals with Opioid Use DisorderK08DA058057 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Suky Martinez · 2024 to 2026
$655kThe Ability of the Inhaled Dronabinol to Reduce the Severity of Naloxone-Precipitated WithdrawalR21DA049076 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI JONES, JERMAINE D · 2020 to 2022
$434kNIDA NIH HHS K08 DA058057NIDA NIH HHS R21 DA049076NIDA NIH HHS T32 DA007294NIH HHS
6 · The paper itselfAbstract
Naloxone administration can precipitate opioid withdrawal, concerns about which may result in hesitancy to use this life-saving intervention. Preclinical and clinical research suggests that cannabinoids may reduce the symptoms associated with opioid withdrawal. This proof-of-concept study sought to test the effects of vaporized cannabis pretreatment (T
Indexed as
CannabinoidsCannabisNaloxoneOpioid-Related DisordersSubstance Withdrawal SyndromeAdministration, IntranasalDose-Response Relationship, DrugHumansMaleNarcotic AntagonistsSeverity of Illness IndexCannabinoidsNaloxoneNarcotic Antagonists
Identifiers
PMID40839512
PMCPMC12590582
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390